|
1.
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar
|
|
2.
|
Long J, Zhang Y, Yu X, Yang J, LeBrun DG,
Chen C, Yao Q and Li M: Overcoming drug resistance in pancreatic
cancer. Expert Opin Ther Targets. 15:817–828. 2011. View Article : Google Scholar
|
|
3.
|
Duffy JP, Eibl G, Reber HA and Hines OJ:
Influence of hypoxia and neoangiogenesis on the growth of
pancreatic cancer. Mol Cancer. 2:122003. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F,
Péré-Vergé D, Delbaldo C, Assenat E, et al: FOLFINOX versus
gemcitabine for metastatic pancreatic cancer. N Engl J Med.
364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Loehrer PJ Sr, Feng Y, Cardenes H, Wagner
L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR
and Benson AB III: Gemcitabine alone versus gemcitabine plus
radiotherapy in patients with locally advanced pancreatic cancer:
an Eastern Cooperative Oncology Group trial. J Clin Oncol.
29:4105–4112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Kim MP and Gallick GE: Gemcitabine
resistance in pancreatic cancer: picking the key players. Clin
Cancer Res. 14:1284–1285. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Marcato P, Dean CA, Giacomantonio CA and
Lee PWK: Aldehyde dehydrogenase: its role as a cancer stem cell
marker comes down to the speficic isoform. Cell Cycle.
10:1378–1384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Dylla SJ, Beviglia L, Park IK, Chartier C,
Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S,
Clarke MF, Hoey T, Lewicki J and Gurney AL: Colorectal cancer stem
cells are enriched in xenogeneic tumors following chemotherapy.
PLoS One. 18:e24282008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Magni M, Shammah S, Schiró R, Mellado W,
Dalla-Favera R and Gianni AM: Induction of
cyclophosphamide-resistance by aldehyde-dehydrogenase gene
transfer. Blood. 87:1097–1103. 1998.PubMed/NCBI
|
|
10.
|
Sládek NE, Kollander R, Sreerama L and
Kiang DT: Cellular levels of aldehyde dehydrogeneases (ALDH1A1 and
ALDH3A1) as predictors of therapeutic responses to
cyclophosphamide-based chemotherapy of breast cancer: a
retrospective study. Rational individualization of
oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer
Chemother Pharmacol. 49:309–321. 2002.
|
|
11.
|
Charafe-Jauffret E, Ginestier C, Iovino F,
Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci
F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH,
Birnbaum D, et al: Aldehyde dehydrogenase 1-positive cancer stem
cells mediate metastasis and poor clinical outcome in inflammatory
breast cancer. Clin Cancer Res. 16:45–55. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Huang EH, Hynes MJ, Zhang T, Ginestier C,
Dontu G, Appelman H, Fields JZ, Wicha MS and Boman BM: Aldehyde
dehydrogenase 1 is a marker for normal and malignant human colonic
stem cells (SC) and tracks SC overpopulation during colon
tumorigenesis. Cancer Res. 69:3382–3389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Su Y, Qui Q, Zhang Z, Jiang Z, Leng Q, Liu
Z, Stass SA and Jiang F: Aldehyde dehydrogenase 1 A1-positive cell
population is enriched in tumor-initiating cells and associated
with progression of bladder cancer. Cancer Epidemiol Biomarkers
Prev. 19:327–337. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Dembinski JL and Krauss S:
Characterization and functional analysis of a slow cycling stem
cell-like subpopulation in pancreas adenocarcinoma. Clin Exp
Metastasis. 26:611–623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Clay MR, Tabor M, Owen JH, Carey TE,
Bradford CR, Wolf GT, Wicha MS and Prince ME: Single-marker
identification of head and neck squamous cell carcinoma cancer stem
cells with aldehyde dehydrogenase. Head Neck. 32:1195–1201. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Jiang F, Qui Q, Khanna A, Todd NW, Deepak
J, Xing L, Wang H, Liu Z, Su Y, Stass SA and Katz RL: Aldehyde
dehydrogenase 1 is a tumor stem cell-associated marker in lung
cancer. Mol Cancer Res. 7:330–338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO,
Zheng BJ and Guan XY: Identification and characterization of
tumorigenic live cancer stem/progenitor cells. Gastroenterology.
132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Landen CN Jr, Goodman B, Katre AA, Steg
AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson
DM, Bast RC Jr, Coleman RL, Lopez-Berestein G and Sood AK:
Targeting aldehyde dehydrogenase cancer stem cells in ovarian
cancer. Mol Cancer Ther. 9:3186–3199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Rasheed ZA, Yang J, Wang Q, Kowalski J,
Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X,
Goggins M, Iacobuzio-Donahue C, Berman DM, Laheru D, Jimeno A,
Hidalgo M, Maitra A and Matsui W: Prognostic significance of
tumorigenic cells with mesenchymal features in pancreatic
adenocarcinoma. J Natl Cancer Inst. 102:340–351. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Duong HQ, Hwang JS, Kim HJ, Kang HJ, Seong
YB and Bae I: Aldehyde dehydrogenase 1A1 confers intrinsic and
acquired resistance to gemcitabine in human pancreatic
adenocarcinoma MIA PaCa-2 cells. Int J Oncol. 41:855–861.
2012.PubMed/NCBI
|
|
21.
|
Araujo J and Logothetis C: Dasatinib: a
potent SRC inhibitor in clinical development for the treatment of
solid tumors. Cancer Treat Rev. 36:492–500. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Kim LC, Rix U and Haura EB: Dasatinib in
solid tomors. Expert Opin Investig Drugs. 19:415–425. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ceppi P, Papotti M, Monica V, Lolanono M,
Saviozzi S, Pautasso M, Novello S, Mussino S, Bracco E, Volante M
and Scagliotti GV: Effects of Src kinase inhibition induced by
dasatinib in non-small cell lung cancer cell lines treated with
cisplatin. Mol Cancer Ther. 8:3066–3074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kopetz S, Lesslie DP, Dallas NA, Park SI,
Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J
and Gallick GE: Synergistic activity of the SRC family kinase
inhibitor dasatinib and oxaliplatin in colon carcinoma cells is
mediated by oxidative stress. Cancer Res. 69:3842–3849. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Nagaraj NS, Washington MK and Merchant NB:
Combined blockade of Src kinase and epidermal growth factor
receptor with gemcitabine overcomes STAT3-mediated resistance of
inhibition of pancreatic tumor growth. Clin Cancer Res. 17:483–493.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Kim YJ, Hong YB, Cho CH, Seong YS and Bae
I: Exploring protein kinase inhibitors: unveiling gemcitabine
resistance in pancreatic cancer. Pancreas. 41:804–805. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Hong DS, Choe JH, Naing A, Wheler JJ,
Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss
LC, Gallick GE and Kurzrock R: A phase 1 study of gemcitabine
combinated with dasatinib in patients with advanced solid tumors.
Invest New Drugs. 31:918–926. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Park BJ, Whichard ZL and Corey SJ:
Dasatinib synergizes with both cytotoxic and signal transduction
inhibitors in heterogeneous breast cancer cell lines - lessons for
design of combination targeted therapy. Cancer Lett. 320:104–110.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Somlo G, Atzori F, Strauss LC, Geese WJ,
Specht JM, Gradishar WJ, Rybicki A, Sy O, Vahdal LT and Cortes J:
Dasatinib plus capecitabine for advanced breast cancer: safety and
efficacy in phase I study CA180004. Clin Cancer Res. 19:1884–1893.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Araujo JC, Mathew P, Armstrong AJ, Braud
EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal
S and Logothetic CJ: Dasatinib combined with docetaxel for
castration-resistant prostate cancer: results from a phase 1–2
study. Cancer. 118:63–71. 2012.PubMed/NCBI
|
|
31.
|
Secord AA, Teoh DK, Barry WT, Yu M,
Broadwater G, Havrilesky LJ, lee PS, Berchuck A, Lancaster J and
Wenham RM: A phase I trial of dasatinib, an SRC-family kinase
inhibitor, in combination with paclitaxel and carboplatin in
patients with advanced or recurrent ovarian cancer. Clin Cancer
Res. 18:5489–5498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Algazi AP, Weber JS, Andrews SC, Urbas P,
Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T
and Daud AI: Phase I clinical trial of the Src inhibitor dasatinib
with dacarbazine in metastatic melanoma. Br J Cancer. 106:85–91.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Breccia M, Serrao A, Salaroli A, Loglisci
G, Zacheo I and Alimena G: Dasatinib combined with weekly
administration of vincristine as effective therapy in sudden or
resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia.
Br J Haematol. 159:612–613. 2012.
|
|
34.
|
Kurebayashi J, Kanomata N, Moriya T,
Kozuka Y, Watanabe M and Sonoo H: Preferential antitumor effect of
the Src inhibitor dasatinib associated with a decreased proportion
of aldehyde dehydrogenase 1-positive cells in breast cancer cells
of the basal B subtype. BMC Cancer. 10:5682010. View Article : Google Scholar
|
|
35.
|
Nautiyal J, Kanwar SS, Yu Y and Majumdar
AP: Combination of dasatinib and curcumin eliminates
chemo-resistant colon cancer cells. J Mol Signal. 6:72011.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Duong HQ, Kim HJ, Kang HJ, Seong YS and
Bae I: ZSTK474, a PI3K inhibitor, suppresses proliferation and
sensitizes human pancreatic adenocarcinoma cells to gemcitabine.
Oncol Rep. 27:182–188. 2012.PubMed/NCBI
|
|
37.
|
Duong HQ, Hong YB, Kim JS, Lee HS, Yi YW,
Kim YJ, Wang A, Zhao W, Cho CH, Seong YS and Bae I: Inhibition of
checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic
adenocarcinoma cells to gemcitabine. J Cell Mol Med. 17:1261–1270.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Nagaraj NS, Smith JJ, Revetta F,
Washington MK and Merchant NB: Targeted inhibition of SRC kinase
signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther.
9:2322–2332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Dick JE: Stem cell concepts renew cancer
research. Blood. 112:4793–4807. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Wang JC and Dick JE: Cancer stem cells:
lesions from leukemia. Trends Cell Biol. 15:494–501. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Yin T, Wei H, Gou S, Shi P, Yang Z, Zhao G
and Wang C: Cancer stem-like cells enriched in panc-1 spheres
possess increased migration ability and resistance to gemcitabine.
Int J Mol Sci. 12:1595–1604. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Hu G, Li F, Ouyang K, Xie F, Tang X, Wang
K, Han S, Jiang Z, Zhu M, Wen D, Qin X and Zhang L: Intrinsic
gemcitabine resistance in a novel pancreatic cancer cell line is
associated with cancer stem cell-like phenotype. Int J Oncol.
40:798–806. 2012.PubMed/NCBI
|
|
43.
|
Hage C, Rausch V, Giese N, Giese T,
Schonsiegel F, Labsch S, Nwaeburu C, Mattern J, Gladkich J and Herr
I: The novel c-Met inhibitor cabozantinib overcomes gemcitabine
resistance and stem cell signaling in pancreatic cancer. Cell Death
Dis. 4:e6272013. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Kim MP, Fleming JB, Wang H, Abbruzzese JL,
Choi W, Kopetz S, McConkey DJ, Evans DB and Gallick GE: ALDH
activity selectively defines an enhanced tumor-initiating cell
population relative to CD133 expression in human pancreatic
adenocarcinoma. PLoS One. 6:e206362011. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Koppaka V, Thompson DC, Chen Y, Ellermann
M, Nicolaou KC, Juvonen RO, Petersen D, Deitrich RA, Hurley TD and
Vasiliou V: Aldehyde dehydrogenase inhibitors: a comprehensive
review on the pharmacology, mechanism of action, substrate
specificity, and clinical application. Pharmacol Rev. 64:520–539.
2012. View Article : Google Scholar
|
|
47.
|
Croker AK and Allan AL: Inhibition of
aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and
radiation resistance of stem-like ALDHhiCD44+ human
breast cancer cells. Breast Cancer Res Treat. 133:75–87. 2012.
View Article : Google Scholar : PubMed/NCBI
|
